Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA test measures the level of prostate-specific antigen in the blood, which can be a sign of prostate cancer.
The main reason for this recommendation is that prostate cancer often grows very slowly. Many older men are more likely to live with the disease than die from it. Treatments can also cause side effects such as urinary problems, fatigue, or sexual difficulties. According to the USPSTF, these harms may outweigh the benefits of detecting the disease early in older men. However, as men today are living longer and healthier lives, some experts believe these guidelines need updating to reflect current medical advancements and improved screening accuracy. The last update was in 2018, and new recommendations are expected soon, potentially changing clinical practice.
Prostate cancer usually begins in the prostate, a small gland in men that produces seminal fluid and plays a key role in male reproductive health. In its early stages, the cancer generally confines to the prostate and often grows slowly. When the cancer becomes metastatic, it spreads to other areas of the body through the blood or lymphatic system. The most common sites for metastasis are the bones, lymph nodes, and sometimes the lungs or liver, which can complicate overall health and mobility.
Metastatic prostate cancer is more serious than localized cancer because it can affect other organs and cause symptoms such as bone pain, fatigue, urinary problems, and weight loss. Treatment usually focuses on slowing the cancer’s growth, managing symptoms, and extending life, rather than curing the disease, although recent advances in therapy, including targeted treatments and immunotherapy, are improving outcomes significantly.
When to Consider Testing
Although it is not routine, some men over 70 still have PSA tests. This usually happens after discussing the pros and cons with their doctor. Often, testing is done when symptoms appear, such as trouble urinating, fatigue, or bone pain.
Marc B. Garnick, Professor of Medicine at Harvard Medical School, explains that it is not uncommon to find advanced prostate cancer in older men through these tests. In many cases, the disease has already spread by the time symptoms appear. This highlights the importance of making screening decisions individually, based on a man’s overall health and life expectancy.
Assessing a Positive PSA Result
If a PSA test suggests that cancer may be present, the next step is usually a prostate needle biopsy. This involves taking small samples of prostate tissue to check for cancer. Doctors also perform a digital rectal examination (DRE) to feel for any lumps or changes in the size or shape of the prostate.
Modern imaging technology now plays an important role in diagnosis. Magnetic resonance imaging (MRI) scans can provide clear, detailed pictures of the prostate. This allows doctors to identify suspicious areas more accurately and take targeted biopsy samples. MRI-guided biopsies are becoming a preferred method because they improve accuracy and help avoid unnecessary procedures.
Assessing Cancer Aggressiveness
Once prostate cancer is confirmed, doctors study the cancer cells under a microscope to determine how aggressive they are. This helps them understand how quickly the cancer may grow and spread. For many years, doctors used the Gleason score to grade prostate cancer. The score ranges from 6 to 10, based on how abnormal the cells look. A score of 6 suggests a slow-growing cancer, while 9 or 10 points to a more dangerous, fast-growing type.
A newer system now groups cancers into five Grade Groups. Grade Group 1 represents the least aggressive cancer, while Grade Group 5 represents the most aggressive form. This simpler system helps patients better understand their diagnosis.
Doctors can also order genetic tests to look for inherited mutations, such as BRCA1 or BRCA2. Men with these mutations are more likely to develop aggressive prostate cancer. These genes are also linked to breast and ovarian cancers, so results can have important implications for family members.
Detecting the Spread
Detecting the spread of prostate cancer involves a combination of imaging studies, laboratory tests, and clinical assessment. Bone scans, CT scans, PET scans, and MRI may be used to determine whether cancer has spread to bones, lymph nodes, liver, lungs, or other organs. Regular monitoring guides treatment decisions and helps manage symptoms over time.
Treatment Goals and Options
In metastatic disease, the primary goals are to slow tumor growth, relieve symptoms, improve quality of life, and extend survival. Treatments may include:
- Hormonal therapy to reduce testosterone levels
- Chemotherapy regimens to slow progression
- Targeted therapies that home in on specific cancer mutations
- Immunotherapy approaches to boost the body’s immune response
- Bone-targeted agents to protect skeletal health and reduce pain
- Palliative care to manage pain, fatigue, and emotional well-being
Newer treatment combinations and sequencing strategies are improving outcomes for many patients. Shared decision-making between patients, families, and clinicians is essential to tailor therapy to individual health status, comorbidities, and personal goals.
Living with Metastatic Prostate Cancer
For men over 70, maintaining functional independence and managing treatment-related side effects are important considerations. Regular physical activity as tolerated, nutrition, and supportive services can help preserve strength and mood. Early integration of palliative care alongside active cancer treatment has been shown to improve symptom control and overall well-being.
Current research continues to explore biomarkers that could predict response to therapies, refine risk stratification, and identify opportunities for precision medicine. Clinicians remain hopeful that ongoing trials will broaden effective options and extend lifespans for men facing metastatic prostate cancer.
Related topics
